When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug ...
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Fidelity Diversified International Fund is a broadly diversified international equity strategy that seeks capital growth by ...
GlobalData on MSN22h
FDA grants accelerated approval for PTC’s AADC deficiency gene therapyThe US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
Zacks.com on MSN17h
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
Fidelity International Capital Appreciation Fund is a diversified international equity strategy that seeks capital growth by ...
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings. Welcome to the iCAD Incorporated Third Quarter 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback